We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sarah Amend

Sarah R Amend PhD

Assistant Professor, The Brady Urological Institute, Johns Hopkins University, Baltimore, MD

Sarah R. Amend, Ph.D., is an Assistant Professor at the Brady Urological Institute at Johns Hopkins University. She received her Ph.D. from Washington University in St. Louis and completed her postdoctoral fellowship at Johns Hopkins University. Dr. Amend’s research program focuses on the early events of prostate cancer metastasis, with specific interest in understanding the critical, though often overlooked, role of the primary tumor in driving lethal disease and resistance to systemic therapy. In particular, she uses evolutionary ecology paradigms to investigate the formation and influences that lead to the generation of cells that eventually seed lethal metastases and actuate tumor therapeutic resistance.